Ignite Creation Date:
2024-05-06 @ 2:58 PM
Last Modification Date:
2024-10-26 @ 1:41 PM
Study NCT ID:
NCT04485676
Status:
COMPLETED
Last Update Posted:
2022-07-22
First Post:
2020-06-16
Brief Title:
Dalbavancin in Real Clinical Practice in Spain
Sponsor:
Angelini Farmacéutica
Organization:
Angelini Farmacéutica
Study Overview
Official Title:
Dalbavancin in Real Clinical Practice in Spain a Two-year Retrospective Study
Status:
COMPLETED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REAL-DAL
Brief Summary:
The aim of this study is to describe the real clinical use of Dalbavancin in Spain between January 2018 and December 2019
Detailed Description:
Dalbavancin is a new lipoglycopeptide approved for the treatment of ABSSSIs Acute Bacterial Skin and Skin-Structure Infections with activity against Gram-positive pathogens including MRSA Dalbavancin has unique pharmacokinetics properties with a terminal half-life of 144 days permitting a single intravenous dosing Dalbavancin has shown a favourable efficacy and safety profile in patients with ABSSSI in randomized controlled trials However information regarding daily clinical practice is limited The main objective of this study is to describe the real clinical practice with Dalbavancin in Spain
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None